ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na ve patients with bone-predominant metastatic castration-resistant prostate cancer.

被引：3
|
作者：
Smith, Matthew R.
Parker, Chris C.
Tombal, Bertrand F.
Miller, Kurt
Saad, Fred
Shen, Junwu
Zhang, Amily
Kornacker, Martin
Higano, Celestia S.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, Sutton, Surrey, England
[4] St Luc Univ Hosp, Brussels, Belgium
[5] Charite, Berlin, Germany
[6] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[7] Bayer, Div Pharmaceut, Whippany, NJ USA
[8] Bayer Pharma AG, Berlin, Germany
[9] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5088
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [22] Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
    van der Poel, Henk
    EUROPEAN UROLOGY, 2019, 76 (05) : 705 - 706
  • [23] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
  • [24] Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.
    Doyle, Catherine Mary
    Mills, Matthew
    Damgaci, Sultan
    Smith, Johnna
    Zhang, Jingsong
    Fishman, Mayer N.
    El-Haddad, Ghassan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Radium-223 in the treatment of bone metastasis in patients with castration-resistant prostate cancer. Review and procedure
    Orcajo-Rincon, J.
    Caresia-Arortegui, A. P.
    del Puig Cozar-Santiago, M.
    Garcia-Garzon, J. R.
    de Arcocha-Torres, M.
    Delgado-Bolton, R. C.
    Garcia-Velloso, M. J.
    Alvarez-Ruiz, S.
    Garcia-Vicente, A. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2018, 37 (05): : 330 - 337
  • [26] Predictors for survival after radium-223 (R223) treatment for castration-resistant metastatic prostate cancer.
    Anderson, Eric
    Wong, William
    Mohammadi, Homan
    Daniels, Thomas Backus
    Tzou, Katherine S.
    Schild, Steven E.
    Keole, Sameer R.
    Choo, Richard
    Bryce, Alan H.
    Thai Huu Ho
    Quevedo, Fernando
    Vora, Sujay A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [28] A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
    Fong, Lawrence
    Morris, Michael J.
    Sartor, Oliver
    Higano, Celestia S.
    Pagliaro, Lance
    Alva, Ajjai
    Appleman, Leonard J.
    Tan, Winston
    Vaishampayan, Ulka
    Porcu, Raphaelle
    Tayama, Darren
    Kadel, Edward E., III
    Yuen, Kobe C.
    Datye, Asim
    Armstrong, Andrew J.
    Petrylak, Daniel P.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4746 - 4756
  • [29] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [30] A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Kim, Stephanie, I
    Szeto, Andy H.
    Morgan, Katherine P.
    Brower, Blaine
    Dunn, Mary W.
    Khandani, Amir H.
    Godley, Paul A.
    Rose, Tracy L.
    Basch, Ethan M.
    Milowsky, Matthew, I
    Whang, Young E.
    Crona, Daniel J.
    PLOS ONE, 2021, 16 (06):
12345